GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (NAS:BCDA) » Definitions » Cyclically Adjusted Price-to-FCF

BCDA (BioCardia) Cyclically Adjusted Price-to-FCF : (As of Jun. 03, 2025)


View and export this data going back to 1995. Start your Free Trial

What is BioCardia Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCardia Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BioCardia's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia Cyclically Adjusted Price-to-FCF Chart

BioCardia Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCardia Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCardia's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, BioCardia's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCardia's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioCardia's Cyclically Adjusted Price-to-FCF falls into.


;
;

BioCardia Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BioCardia's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, BioCardia's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.349/134.9266*134.9266
=-0.349

Current CPI (Mar. 2025) = 134.9266.

BioCardia Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.634 100.684 0.850
201509 0.268 100.392 0.360
201512 0.803 99.792 1.086
201603 0.599 100.470 0.804
201606 -0.373 101.688 -0.495
201609 39.190 101.861 51.912
201612 -39.429 101.863 -52.227
201703 -8.276 102.862 -10.856
201706 -7.516 103.349 -9.812
201709 -6.304 104.136 -8.168
201712 -9.025 104.011 -11.708
201803 -10.746 105.290 -13.771
201806 -9.961 106.317 -12.642
201809 -7.092 106.507 -8.984
201812 -11.362 105.998 -14.463
201903 -8.905 107.251 -11.203
201906 -7.186 108.070 -8.972
201909 -3.711 108.329 -4.622
201912 -7.192 108.420 -8.950
202003 -6.589 108.902 -8.164
202006 -4.566 108.767 -5.664
202009 -4.313 109.815 -5.299
202012 -3.857 109.897 -4.735
202103 -1.729 111.754 -2.088
202106 -2.547 114.631 -2.998
202109 -2.340 115.734 -2.728
202112 -2.650 117.630 -3.040
202203 -2.585 121.301 -2.875
202206 -2.268 125.017 -2.448
202209 -1.697 125.227 -1.828
202212 -2.456 125.222 -2.646
202303 -1.911 127.348 -2.025
202306 -2.320 128.729 -2.432
202309 -1.674 129.860 -1.739
202312 -1.232 129.419 -1.284
202403 -0.913 131.776 -0.935
202406 -0.699 132.554 -0.712
202409 -0.924 133.029 -0.937
202412 -0.559 133.157 -0.566
202503 -0.349 134.927 -0.349

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioCardia  (NAS:BCDA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BioCardia Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BioCardia's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCardia Business Description

Industry
Traded in Other Exchanges
N/A
Address
320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Executives
Peter Altman director, officer: President and CEO C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Bill Facteau director C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE CA 94085
David Mcclung officer: VP of Finance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Richard M Krasno director C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 31337
Andrew Scott Blank director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Simon H Stertzer director C/O BIOCARDIA, INC., 125 SHOREWAY DRIVE, SUITE B, SAN CARLOS CA 94070
Edward M Gillis officer: Senior Vice President, Devices C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Krisztina M Zsebo director C/O CELLADON CORPORATION, 12760 HIGH BLUFF DRIVE, SUITE 240, SAN DIEGO CA 92130
Jim L. Allen director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Stertzer Family Trust 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Kimberly Stertzer 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Allan R Tessler director C/O EPOCH HOLDING CORPORATION, 640 FIFTH AVENUE, NEW YORK, NY 10019
Jay M Moyes director